[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
December 27, 1995

Serum Gonadotropins and Steroid Hormones and the Development of Ovarian Cancer

Author Affiliations

From the Department of Epidemiology, School of Hygiene and Public Health (Drs Helzlsouer, Alberg, Bush, and Comstock and Ms Hoffman), and the Department of Oncology, School of Medicine (Drs Helzlsouer and Gordon), The Johns Hopkins University, Baltimore, Md; and the Department of Obstetrics and Gynecology, University of Massachusetts Medical Center, Worcester (Dr Longcope).

JAMA. 1995;274(24):1926-1930. doi:10.1001/jama.1995.03530240036037

Objective.  —To prospectively examine the association between endogenous hormones and development of ovarian cancer.

Design.  —Nested case-control study.

Setting.  —A population-based serum bank in Washington County, Maryland.

Participants.  —Serum samples were collected in 1974 from 20 305 county residents and stored at -70°C. From 1975 through 1989, a total of 31 cases of ovarian cancer were identified in women who were not taking hormones at the time of blood collection. These cases were matched to 62 controls on age, menopausal status, and, for premenopausal women, number of days from the beginning of the last menstrual period.

Main Outcome Measure.  —Prediagnostic endogenous hormone levels of cases and controls were compared.

Results.  —Mean follicle-stimulating hormone levels were lower among cases (43.3 IU/L) compared with controls (54.4 IU/L) (P=.04), and increasing levels were associated with significantly lower risk (P for trend=.01), particularly among postmenopausal women. Luteinizing hormone levels were 9% lower among cases than controls, but the difference was not statistically significant (P=.39). Compared with controls, cases had higher androstenedione levels (4.5 nmol/L vs 3.3 nmol; P=.03) and higher dehydroepiandrosterone (DHEA) levels (15.9 nmol/L vs 9.7 nmol/L; P=.02). The risk of ovarian cancer increased with higher levels of androstenedione and DHEA sulfate (P for trend=.008 and.11, respectively). These associations were not materially different between premenopausal and postmenopausal women.

Conclusion.  —The results suggest that women with low serum gonadotropin levels or high androgen levels have an increased risk of ovarian cancer. These findings do not support the hypothesis that pituitary gonadotropins increase the risk of ovarian cancer. Replication of the study in other populations is highly desirable.(JAMA. 1995;274:1926-1930)